Gilead Sciences, Inc. today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company's injectable HIV-1 capsid inhibitor, ...

The program comprises five HIV prevention trials around the world that are focused on innovation in science, trial design ... at www.gilead.com. Gilead and the Gilead logo, Truvada, and Truvada ...

The cityscape just behind the Hollywood sign keeps the early to mid 20th century alive, thriving and center stage.

Logos aren’t just there to look pretty or to label your brand; they should be designed purposefully, with meaning behind each design element.

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $120.00. The company’s shares closed yesterday at $114.43.

In this article, we are going to take a look at where Gilead Sciences Inc (NASDAQ:GILD) stands against other top stocks Wall Street is discussing. Bill Strazzullo, Bell Curve Trading chief market ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other best pharma stocks to buy according to hedge funds. The US pharmaceutical sector ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Also Read: Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention At CROI 2025, the primary results of a Phase 2 study evaluating lenacapavir (LEN) with teropavimab (TAB) and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...